Treating Parkinson's disease in the 21st century: Can stem cell transplantation compete?

Authors

  • Philip C. Buttery,

    Corresponding author
    1. John van Geest Centre for Brain Repair, University of Cambridge, Cambridge, United Kingdom
    • Correspondence to: Philip C. Buttery, University of Cambridge, John van Geest Centre for Brain Repair, E.D. Adrian Building, Forvie Site, Robinson Way, Cambridge CB2 0PY, UK. E-mail: pcb10@cam.ac.uk.

    Search for more papers by this author
  • Roger A. Barker

    1. Wellcome Trust - Medical Research Council Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom
    Search for more papers by this author

  • The copyright line for this article was changed on April 3, 2015 after original online publication.

ABSTRACT

The characteristic and selective degeneration of a unique population of cells—the nigrostriatal dopamine (DA) neurons—that occurs in Parkinson's disease (PD) has made the condition an iconic target for cell replacement therapies. Indeed, transplantation of fetal ventral mesencephalic cells into the DA-deficient striatum was first trialled nearly 30 years ago, at a time when other treatments for the disease were less well developed. Over recent decades standard treatments for PD have advanced, and newer biological therapies are now emerging. In the 21st century, stem cell technology will have to compete alongside other sophisticated treatments, including deep brain stimulation and gene therapies. In this review we examine how stem cell–based transplantation therapies compare with these novel and emerging treatments in the management of this common condition. J. Comp. Neurol. 522:2802–2816, 2014. © 2014 The Authors The Journal of Comparative Neurology Published by Wiley Periodicals, Inc.

Ancillary